title: Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration.
abstract: To induce and activate tumor-associated antigen-specific cytotoxic T lymphocytes (CTLs) for cancer immunity, it is important not only to select potent CTL epitopes but also to combine them with appropriate immunopotentiating agents. Here we investigated whether tumor immunity induced by WT1 peptide vaccination could be enhanced by IFN-β. For the experimental group, C57BL/6 mice were twice pre-treated with WT1 peptide vaccine, implanted with WT1-expressing C1498 cells, and treated four times with WT1 peptide vaccine at one-week intervals. During the vaccination period, IFN-β was injected three times a week. Mice in control groups were treated with WT1 peptide alone, IFN-β alone, or PBS alone. The mice in the experimental group rejected tumor cells and survived significantly longer than mice in the control groups. The overall survival on day 75 was 40% for the mice treated with WT1 peptide+IFN-β, while it was 7, 7, and 0% for those treated with WT1 peptide alone, IFN-β alone or PBS alone, respectively. Induction of WT1-specific CTLs and enhancement of NK activity were detected in splenocytes from mice in the experimental group. Furthermore, administration of IFN-β enhanced expression of MHC class I molecules on the implanted tumor cells. In conclusion, our results showed that co-administration of WT1 peptide+IFN-β enhanced tumor immunity mainly through the induction of WT1-specific CTLs, enhancement of NK activity, and promotion of MHC class I expression on the tumor cells. WT1 peptide vaccination combined with IFN-β administration can thus be expected to enhance the clinical efficacy of WT1 immunotherapy.
authors: Department of Cancer Immunology, Osaka University Graduate School of Medicine, Osaka, Japan.
authors: Hiroko
authors: H
authors: Nakajima
authors: Yoshihiro
authors: Y
authors: Oka
authors: Akihiro
authors: A
authors: Tsuboi
authors: Naoya
authors: N
authors: Tatsumi
authors: Yumiko
authors: Y
authors: Yamamoto
authors: Fumihiro
authors: F
authors: Fujiki
authors: Zheyu
authors: Z
authors: Li
authors: Ayako
authors: A
authors: Murao
authors: Soyoko
authors: S
authors: Morimoto
authors: Naoki
authors: N
authors: Hosen
authors: Toshiaki
authors: T
authors: Shirakata
authors: Sumiyuki
authors: S
authors: Nishida
authors: Ichiro
authors: I
authors: Kawase
authors: Yoshitaka
authors: Y
authors: Isaka
authors: Yusuke
authors: Y
authors: Oji
authors: Haruo
authors: H
authors: Sugiyama
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D016899:Interferon-beta / Q000008:administration & dosage*; D007680:Kidney Neoplasms / Q000276:immunology / Q000517:prevention & control*; D007694:Killer Cells, Natural / Q000276:immunology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D013154:Spleen / Q000276:immunology; D016019:Survival Analysis; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D025721:WT1 Proteins / Q000008:administration & dosage / Q000276:immunology*; D009396:Wilms Tumor / Q000276:immunology / Q000517:prevention & control*
chemical_list: D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D025721:WT1 Proteins; D016899:Interferon-beta